Search clinical trials for: Navarixin 1 mg

Total 23074 results

Merck Sharp & Dohme LLC

Terminated

Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)

Chronic Obstructive Pulmonary Disease
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009)

Psoriasis
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363)

Asthma
Merck Sharp & Dohme LLC

Terminated

Long-Term Study of the Effects of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe COPD (MK-7123-019)

COPD
Dompé Farmaceutici S.p.A

Completed

A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy Volunteers

no Condition

Switzerland
Dompé Farmaceutici S.p.A

Terminated

A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

New-onset Type 1 Diabetes

United States, Belgium, Georgia, Germany, Italy, Serbia
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

Attention Deficit Disorder With Hyperactivity

United States
Pfizer

Completed

Multiple Oral Doses Of PH-797804 In Healthy Japanese Adult Subjects

Healthy

United States
Merck Sharp & Dohme LLC

Completed

Neutrophilic Asthma Study With Navarixin (MK-7123, SCH 527123) (MK-7123-017)(COMPLETED)

Neutrophilic Asthma
Johnson & Johnson K.K. Medical Company

Completed

Open-Label Study for Shoulder Dislocation Using MG-1 (MG-1)

Shoulder Dislocation

Japan
Dompé Farmaceutici S.p.A

Completed

A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes

Diabetes Mellitus, Insulin-Dependent

Germany, Belgium, Italy
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Non-small Cell Lung Cancer | Solid Tumors | Castration Resistant Prostate Cancer | Microsatellite Stable Colorectal Cancer

Canada, United States, Australia, Israel, Korea, Republic of
GlaxoSmithKline

Completed

PK Study of IV Formulation of GW856553

Cardiovascular Disease

United Kingdom
Bio Sidus SA

Completed

PK/PD Study of 2 Agalsidase Formulations in Single Dose of 1 mg/kg Administered to Healthy Volunteers as IV Infusion

Fabry Disease

Argentina
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (APECS)

Alzheimer's Disease | Amnestic Mild Cognitive Impairment | Prodromal Alzheimer's Disease
Galderma R&D

Completed

Performance of Different Application Regimens of ACTINICA® on Protection From UVR-induced Erythema After One Day of Sun Exposure in Fair-skinned Healthy Subjects.

Healthy Subjects, Male or Female, of 18-60 Years Old, With Phototype I, II or III, Not Pre-treated/Pre-protected Skin

France
Ain Shams University

Completed

Doubling the Iron Dose to Prevent IDA in Twin Pregnant Women (IDA)

Hematologic Pregnancy Complications

Egypt
Sunovion

Completed

Dasotraline SEP360-105 Pediatric PK/PD Study

Pediatric Attention Deficit Hyperactivity Disorder

United States
Zydus Therapeutics Inc.

Recruiting

Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis (EPICS-III)

Primary Biliary Cholangitis

United States, Argentina, Iceland, Turkey
Gannex Pharma Co., Ltd.
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
AM-Pharma

Completed

Recombinant Human Alkaline Phosphatase in Healthy Japanese Subjects

Healthy

Japan
Idorsia Pharmaceuticals Ltd.

Completed

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Spain, United States, Italy, Taiwan, Thailand, Poland, Russian Federation, Israel, Ukraine, Mexico, Philippines, Georgia, United Kingdom, Chile, France, Bulgaria, Czechia, Greece, Hungary, Romania, Turkey, Germany, Puerto Rico, Japan
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

Diabetic Neuropathy

United States
Zydus Therapeutics Inc.

Suspended

Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL

Dyslipidemias

United States
Shire

Completed

A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®

Hunter Syndrome

United States, United Kingdom
Arena Pharmaceuticals

Completed

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis (ADVISE)

Atopic Dermatitis

United States, Australia, Canada
Endo Pharmaceuticals

Completed

AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder

Adhesive Capsulitis | Frozen Shoulder

United States
GlaxoSmithKline

Completed

First Time in Human Study Using GSK2330672

Diabetes Mellitus, Type 2

United States
Pfizer

Active, not recruiting

A Study to Learn How Different Forms of Study Medicine Tafamidis Are Taken Up Into The Blood in Healthy Adults

Healthy

Belgium
MedImmune LLC
AstraZeneca

Terminated

A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Mexico, Peru, South Africa, Canada
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

Healthy Subjects

United States
Dompé Farmaceutici S.p.A

Terminated

Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes. (CONSERVA)

Type 1 Diabetes

Italy
Dompé Farmaceutici S.p.A

Withdrawn

Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes

Type I Diabetes

United States
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.

Healthy

United States
Idorsia Pharmaceuticals Ltd.

Completed

Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH) (CONSCIOUS-1)

Aneurysmal Subarachnoid Hemorrhage

United States, Canada
Kadmon Corporation, LLC
Quotient Sciences

Completed

A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability

Healthy Volunteers

United Kingdom
RECORDATI GROUP

Completed

Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury

Neurogenic Detrusor Overactivity

Czechia, France, Poland, Portugal
Pfizer

Completed

A Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects

Healthy Volunteers

Belgium
Vantia Ltd

Completed

Dose Range Finding Study of Fedovapagon in Men With Nocturia

Nocturia

United States
Pfizer

Terminated

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson Disease

United States, Spain, Canada, France, Japan, Germany
LG Life Sciences

Completed

Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg

Hypertension | Hyperlipidemia

Korea, Republic of
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Nasopharyngeal Carcinoma | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
NoNO Inc.
University of Calgary

Completed

Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke (ESCAPE-NA1)

Stroke, Acute

United States, Ireland, Korea, Republic of, Canada, Sweden, Germany, United Kingdom, Australia
Celgene

Completed

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

Healthy

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma

Asthma

United States, Canada
Nocion Therapeutics

Completed

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

Refractory Chronic Cough

United States
Pfizer

Completed

First Safety Study in Humans of a Single Dose of CPG 52364

Healthy Volunteers

United States
H. Lundbeck A/S

Terminated

Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia

Schizophrenia

Bulgaria, Czechia, Estonia, Germany, Hungary, Latvia, Poland, Ukraine
Pila Pharma

Completed

A Single-dose Trial to Investigate the Safety and Tolerability of XEN-D0501 in Patients With Diabetes Mellitus Type 2

Diabetes Mellitus, Type 2

Denmark
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Phase I Study of Direct Coagulation Factor Xa Inhibitor SYHA136 Tablets in Chinese Healthy Volunteers

Venous Thrombosis

3

Subscribe